Davis Polk advised the placement agent in connection with a private placement pursuant to Rule 4(a)(2) by Humanigen Inc. of $72 million of common stock.

Humanigen Inc. is a clinical stage biopharmaceutical company that is developing a portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases through its GM-CSF neutralization and gene-knockout platforms in order to reduce the inflammatory cascade associated with COVID-19, as well as CAR-T therapy-related side effects.

The Davis Polk capital markets team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associate Jacqueline Marino. All members of the Davis Polk team are based in the New York office.

Copy link to share post